PHAT's risk score sits below the engine's floor and options positioning signals heavy hedging, but a perfect earnings-beat streak, 104% revenue growth, and an elite Rule of 40 score temper the risk-driven exit signal.
Thesis pillars
- Risk Below Floor↑Improving
- Elevated Put Call And Implied Vol↑Improving
- Perfect Earnings Beat Streak With Strong Growth→Stable
- +1 more pillar — see the Why tab for full reasoning
Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $6.99, but acceptable to hold if already in. Reasons: Concentration risk — Product: VOQUEZNA; Concentration risk — Counterparty: Takeda License.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal... Read more
Hold if already holding. Not a fresh buy at $6.99, but acceptable to hold if already in. Reasons: Concentration risk — Product: VOQUEZNA; Concentration risk — Counterparty: Takeda License. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Mixed signals. Hold existing position. Score 6.6/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-09-24Recent Developments — Phathom Pharmaceuticals, Inc.
Latest news
- NEWS Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q2 2026 Result - GuruFocus — GuruFocus neutral
- NEWS Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence - TradingKey — TradingKey neutral
- NEWS Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Report - Results, Call & Slides - TipRanks — TipRanks neutral
- NEWS Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Report - Results, Call & Slides - tipranks.com — tipranks.com neutral
- NEWS Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛 — 富途牛牛 neutral
Generated 2026-09-24T04:12:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVOQUEZNA10-K Item 1A: 'We currently depend entirely on the success of our approved VOQUEZNA products, and in particular on the success of VOQUEZNA for the treatment of GERD.'
- HIGHcounterpartyTakeda License10-K Item 1A: 'We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $6.99, but acceptable to hold if already in. Reasons: Concentration risk — Product: VOQUEZNA; Concentration risk — Counterparty: Takeda License. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Mixed signals. Hold existing position. Target $17.80 (+154.8%), stop $6.77 (−3.2%), A.R:R 10.8:1. Score 6.6/10, moderate confidence.
Take-profit target: $17.80 (+154.8% upside). Target $17.80 (+154.8%), stop $6.77 (−3.2%), A.R:R 10.8:1. Stop-loss: $6.77.
Concentration risk — Product: VOQUEZNA; Concentration risk — Counterparty: Takeda License; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4).
Phathom Pharmaceuticals, Inc. trades at a P/E of N/A (forward 7.2). TrendMatrix value score: 9.1/10. Verdict: Hold.
17 analysts cover PHAT with a consensus score of 4.2/5. Average price target: $20.
What does Phathom Pharmaceuticals, Inc. do?Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for...
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.